Introgen’s Drug Candidate Advances to Second Phase II Clinical Trial

Introgen Therapeutics and Moffitt Cancer Center will begin a Phase II randomized, controlled study of INGN 225, Introgen’s investigational immunotherapy product in patients with metastatic small-cell lung cancer.

INGN 225 is an immunotherapy using a patient’s own cells to stimulate an antitumor immune response to fight cancer. The immunotherapeutic targets a molecular abnormality found in more than half of all solid cancers.

The National Institutes of Health National Cancer Institute awarded a grant of approximately $1.3 million to fund this trial, which is expected to enroll as many as 80 patients, according to Introgen and the Moffitt Cancer Center.